Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

NCT02738151 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

929

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Insulin glargine, 300U/mL
DRUG: Insulin degludec, 100 U/mL
DRUG: Non-insulin anti-diabetic treatment

Sponsor

Sanofi